Abstracts Archive - Page 2003 of 2607 - ACR Meeting Abstracts

Abstract Number: 1984 • 2015 ACR/ARHP Annual Meeting
Incidence and Intensity of 18fdg Uptake on Whole Body PET/CT in Patients with Polymyalgia Rheumatica
Claire Owen^1,2, Aurora Poon^3,4, Sze Ting Lee^2,3,4, Christine McMenamin¹, Kunthi Pathmaraj³, Andrew Scott^2,3,4 and Russell Buchanan^1,2, ¹Rheumatology, Austin Health, Heidelberg VIC, Australia, ²Medicine, University of Melbourne, Parkville VIC, Australia, ³Department of Molecular Imaging and Therapy, Austin Health, Heidelberg VIC, Australia, ⁴Olivia Newton-John Cancer Research Institute, Heidelberg VIC, Australia
Incidence and Intensity of 18FDG Uptake on Whole Body PET/CT in Patients with Polymyalgia Rheumatica C.E. Owen1,2, A.M.T. Poon2,3, S.T. Lee2,3,4, K. Pathmakaj3, C. McMenamin1,…
Abstract Number: 1985 • 2015 ACR/ARHP Annual Meeting
Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica
Guillermo Carvajal Alegria¹, Valerie Devauchelle², Yves Renaudineau³, Alain Saraux⁴, Jacques-Olivier Pers⁵ and Divi Cornec⁶, ¹Immunology, CHRU MORVAN, BREST, France, ²Service de Rhumatologie, CHU Brest, Brest, France, ³Immunology, Brest University Medical School Hospital, Brest, France, ⁴Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁵EA2216/ERI29 UBO, Brest, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France
Background/Purpose: Abnormalities in B-cell population distribution were recently reported in polymyalgia rheumatica (PMR) and giant cell arteritis, which improved with glucocorticoids. Our objective here was…
Abstract Number: 1986 • 2015 ACR/ARHP Annual Meeting
Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Eric Toussirot¹, Antoine Martin², Martin Soubrier³, serge redeker⁴, Alexis Régent⁵ and Le CRI⁶, ¹Service de Rhumatologie, CHU J Minjoz, Besancon, France, ²Rheumatology, Centre Hospitalier, St Brieuc, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴43 rue de l'isle, Ch Abbeville, Abbeville, France, ⁵Paris Descartes University, UPRES-EA 4058, Paris, France, ⁶Rheumatology, CHU, Strasbourg, France
Background/Purpose: polymyalgia rheumatic (PMR) is a chronic inflammatory disorder of unknown etiology that affects elderly people. Glucocorticoids (GC) are still the mainstay of therapy for…
Abstract Number: 1987 • 2015 ACR/ARHP Annual Meeting
Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study
Valerie Devauchelle¹, Alain Saraux², Jean-Marie Berthelot³, Divi Cornec⁴, Yves Renaudineau⁵, Sandrine Jousse-Joulin¹, Thierry Marhadour⁶, Solene Querellou⁷, Florent Garrigues⁸, Michel De Bandt⁹ and Maelenn Gouillou¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ³Rheumatology, University Hospital, Nantes, France, ⁴Department of rheumatology, Brest Occidentale University, Brest, France, ⁵Immunology, Brest University Medical School Hospital, Brest, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Nuclear Medicine Department, Morvan University Hospital, Brest, France, ⁸Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁹Rheumatology department, CHU Fort de France, Fort de France, France, ¹⁰Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
Background/Purpose: Glucocorticoids (GCs) are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce several adverse events. Methods: Objectives: To evaluate efficacy and safety of tocilizumab…
Abstract Number: 1988 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases
Ryo Rokutanda¹, Chisun Min², Yuko Kataoka¹, Tokutaro Tsuda¹, Shunya Kaneshita¹, Ken-ichi Yamaguchi³, Koji Takasugi⁴, Masei Suda¹, Akira Takeda³, Yukio Matsui^1,3, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴Imuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease characterized by aching and morning stiffness of body, which is seen almost exclusively in adults over…
Abstract Number: 1989 • 2015 ACR/ARHP Annual Meeting
Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Montserrat Santos-Gómez¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Santos Castañeda³, Norberto Ortego-Centeno⁴, M. Enriqueta Peiró¹, Paz Collado⁵, Sheila Melchor⁶, Antonio Mera⁷, Eva Pérez-Pampin⁸, Esteban Rubio Romero⁹, Jaime Calvo-Alen¹⁰, Elena Aurrecoechea¹¹, Iñigo Rúa-Figueroa¹², Mauricio Minguez¹³, Gabriel Herrero-Beaumont¹⁴, Beatriz Bravo¹⁵, José Rosas¹⁶, Javier Narváez¹⁷, Javier Calvo¹⁸, Rafael Ariza-Ariza¹⁹, Mercedes Freire²⁰, Pablo Lluch Mesquida²¹, Cristina Mata²², Eva Galindez-Agirregoikoa²³, Juan María Blanco Madrigal²³, Amalia Sánchez²⁴, José Salvatierra²⁵, Vanesa Calvo-Río¹, Carmen Gonzalez-Vela²⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, ⁴Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ⁵Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario de Santiago de Compostela, La Coruña, Spain, ⁸Rheumatology, Hospital Universitario de Santiago de Compostela, La coruña, Spain, ⁹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Rheumatology Division, Hospital de Sierrallana, Torrelavega, Spain, ¹¹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹²Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ¹³Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain, ¹⁴Department of Osteoarticular Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹⁵Pediatric rheumatology, Hospital Virgen de las Nieves, Granada, Spain, ¹⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Rheumatology, Hospital General Consorcio de Valencia, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁰Rheumatology, Complejo Hospitalario Universitario de A Coruña, La Coruna, Spain, ²¹Hospital Mateu Orfila, Mahón (Menorca), Spain, ²²Rheumatology, Hospital de Sierrallana, Laredo, Spain, ²³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Hospital Lucus Augusti, Lugo, Spain, ²⁵Hospital Universitario de San Cecilio, Granada, Spain, ²⁶Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Aortitis is often refractory to conventional immunosuppressive (IS) therapy. The use of biological therapy, such as tocilizumab (TCZ) and anti-TNFα agents have been…
Abstract Number: 1990 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Use in Idiopathic Aortitis: A Systematic Review
Nancy Maltez¹ and Nataliya Milman², ¹Internal Medicine, University of Ottawa, Ottawa, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Idiopathic aortitis (IA) is a poorly defined entity with no specific pathological or clinical criteria for its classification or diagnosis, except for the presence…
Abstract Number: 1991 • 2015 ACR/ARHP Annual Meeting
Large Vessel Involvement By IgG4-Related Disease
Cory Perugino¹, Zachary Wallace¹ and John H. Stone², ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition of uncertain etiology. Reports have described inflammatory aortitis and peri-aortitis in the setting of retroperitoneal fibrosis…
Abstract Number: 1992 • 2015 ACR/ARHP Annual Meeting
Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome
Seby John¹, Leonard H. Calabrese², Juan J. Maya³, Alex Massiello⁴, Ken Uchino¹, Serpil Erzurum⁵, Allison Janocha⁵ and Rula A Hajj-Ali⁶, ¹Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ³Internal Medicine, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Plasma Endothelin-1 parallels the vasoconstriction phase in Reversible Cerebral Vasoconstriction SyndromeBackground/Purpose: Cerebral vasoconstriction is thought to be the underlying pathogenetic mechanism of Reversible Cerebral Vasoconstriction…
Abstract Number: 1993 • 2015 ACR/ARHP Annual Meeting
Imaging Findings of Cerebral Amyloid Angiopathy, Abeta-Related Angiitis (ABRA) and Cerebral Amyloid Angiopathy-Related Inflammation: A Single Institution 25 Year Experience
Carlo Salvarani¹, Jonathan M Morris², Caterina Giannini², Teresa J. H. Christianson³, Robert D. Brown Jr.⁴ and Gene G. Hunder⁵, ¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, ⁴Department of Neurology, Mayo Clinic, Rochester, MN, ⁵Dept Internal Med/Rheum, Mayo Clinic, Rochester, MN
Background/Purpose: To investigate the role of imaging in differentiating cerebral amyloid angiopathy (CAA) with and without inflammation. Methods: We studied 54 patients seen over 25…
Abstract Number: 1994 • 2015 ACR/ARHP Annual Meeting
Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus : A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual
Yasser M. El Miedany¹, Sami Bahlas², Maha El Gaafary³, Sally Youssef⁴ and Ihab Ahmed⁵, ¹Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, ²Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ³Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, ⁴Rheumatology and Rehabilitation Departmennt, Ain Shams University, Cairo, Egypt, ⁵Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Patient reported outcomes measures (PROMs) are changing the landscape in rheumatology care. Electronic PROMs (ePROMs) is a new patient-centric model of collaboration that fully…
Abstract Number: 1995 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?
Sofia Pedro¹, Ted R. Mikuls² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Elderly-onset RA (EORA) patients (age of onset>60) are less likely to be treated with biologics even when accounting for disease activity compared to young-onset…
Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…
Abstract Number: 1998 • 2015 ACR/ARHP Annual Meeting
A National Electronic Health Record-Enabled Registry in Rheumatology: The ACR’s Rheumatology Informatics System for Effectiveness (RISE)
Jinoos Yazdany¹, Rachel Myslinski², Melissa Francisco³, Nick Bansback⁴, Megan E. B. Clowse⁵, Deborah Collier⁶, Karen Law⁷, Katherine Liao⁸, Kaleb Michaud⁹, Esi Morgan-DeWitt¹⁰, Jim Oates¹¹, Catalina Orozco¹², Andreas Reimold¹³, Julia F Simard¹⁴ and Salahuddin Kazi¹⁵, ¹University of California, San Francisco, San Francisco, CA, ²Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ³Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ⁴Population and Public Health, The University of British Columbia, Vancouver, BC, Canada, ⁵Clinical Rheumatologist, Duke University Medical Center, Durham, NC, ⁶Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Emory University School of Medicine, Atlanta, GA, ⁸Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Medicine, Medical University of South Carolina, Charleston, SC, ¹²Arthritis Consultation Ctr, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ¹⁵Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX
Title: A National Electronic Health Record-Enabled Registry in Rheumatology: The ACR's Rheumatology Informatics System for Effectiveness (RISE)Background/Purpose: In 2014, the ACR launched the Rheumatology Informatics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].